65
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent psychiatric disorder in children/adolescents. This study reviews available European-based studies of ADHD-related costs and applies the findings to the Netherlands to estimate annual national costs for children/adolescents from a societal perspective. A systematic literature search was conducted for primary studies in Europe, published January 1, 1990 through April 23, 2013. Per-person cost estimates were converted to 2012 Euros and used to estimate annual national ADHD-related costs based on the Dutch 2011 census, ADHD prevalence rates, family composition, and employment rates. Seven studies met the inclusion criteria. The average total ADHD-related costs ranged from €9,860 to €14,483 per patient and annual national costs were between €1,041 and €1,529 million (M). The largest cost category was education (€648 M), representing 62 and 42 % of the low- and high-value overall national estimates, respectively. By comparison, ADHD patient healthcare costs ranged between €84 M (8 %) and €377 M (25 %), and social services costs were €4.3 M (0.3–0.4 %). While the majority of the costs were incurred by ADHD patients themselves, €161 M (11–15 %) was healthcare costs to family members that were attributable to having an ADHD child/adolescent. In addition, productivity losses of family members were €143–€339 M (14–22 %). Despite uncertainties because of the small number of studies identified and the wide range in the national cost estimates, our results suggest that ADHD imposes a significant economic burden on multiple public sectors in Europe. The limited number of European-based studies examining the economic burden of ADHD highlights the need for more research in this area.

          Electronic supplementary material

          The online version of this article (doi:10.1007/s00787-013-0477-8) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.

          This practice parameter describes the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) based on the current scientific evidence and clinical consensus of experts in the field. This parameter discusses the clinical evaluation for ADHD, comorbid conditions associated with ADHD, research on the etiology of the disorder, and psychopharmacological and psychosocial interventions for ADHD.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Medication for attention deficit-hyperactivity disorder and criminality.

              Attention deficit-hyperactivity disorder (ADHD) is a common disorder that has been associated with criminal behavior in some studies. Pharmacologic treatment is available for ADHD and may reduce the risk of criminality. Using Swedish national registers, we gathered information on 25,656 patients with a diagnosis of ADHD, their pharmacologic treatment, and subsequent criminal convictions in Sweden from 2006 through 2009. We used stratified Cox regression analyses to compare the rate of criminality while the patients were receiving ADHD medication, as compared with the rate for the same patients while not receiving medication. As compared with nonmedication periods, among patients receiving ADHD medication, there was a significant reduction of 32% in the criminality rate for men (adjusted hazard ratio, 0.68; 95% confidence interval [CI], 0.63 to 0.73) and 41% for women (hazard ratio, 0.59; 95% CI, 0.50 to 0.70). The rate reduction remained between 17% and 46% in sensitivity analyses among men, with factors that included different types of drugs (e.g., stimulant vs. nonstimulant) and outcomes (e.g., type of crime). Among patients with ADHD, rates of criminality were lower during periods when they were receiving ADHD medication. These findings raise the possibility that the use of medication reduces the risk of criminality among patients with ADHD. (Funded by the Swedish Research Council and others.).
                Bookmark

                Author and article information

                Contributors
                h.h.le@rug.nl
                +1-484-5958256 , +1-484-5958178 , phodgkins@shire.com
                m.j.postma@rug.nl
                jkahle@bpsintl.com
                vsikirica@shire.com
                jsetyawan@shire.com
                herder@shire.com
                jdoshi@mail.med.upenn.edu
                Journal
                Eur Child Adolesc Psychiatry
                Eur Child Adolesc Psychiatry
                European Child & Adolescent Psychiatry
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                1018-8827
                1435-165X
                29 October 2013
                29 October 2013
                2014
                : 23
                : 587-598
                Affiliations
                [ ]PharmacoEpidemiology & PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1, 9713 Groningen, The Netherlands
                [ ]Global Health Economics and Outcomes Research, Shire, 725 Chesterbrook Boulevard, Wayne, PA 19087 USA
                [ ]BPS International, 3830 Valley Centre #705 PMB503, San Diego, CA 92130 USA
                [ ]General Internal Medicine, University of Pennsylvania, 1222 Blockley Hall, Philadelphia, PA 19104-6021 USA
                Article
                477
                10.1007/s00787-013-0477-8
                4077218
                24166532
                ef95f28d-9939-4d9b-add9-f2af060dfd03
                © The Author(s) 2013

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

                History
                : 4 April 2013
                : 24 September 2013
                Categories
                Original Contribution
                Custom metadata
                © Springer-Verlag Berlin Heidelberg 2014

                Clinical Psychology & Psychiatry
                attention-deficit/hyperactivity disorder,children,adolescents,cost of illness,societal costs

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content81

                Cited by50

                Most referenced authors960